Filtern Sie alle Angebote nach Fachbereich

CALMponin - Novel markers for the diagnosis and prognosis of breast cancer



Ref.-Nr. 2864

The invention is based on the finding that the proteins Calmodulin-like protein 5 (CALML5) and Calponin-h2 (CNN2) are upregulated in the nuclear matrix of human breast cancer tissue whereas both are absent in healthy human breast tissue and benign controls. Thus, the two proteins may serve as novel markers for breast cancer.

Comparing levels of CNN2 and CALML5 in human blood of patients with breast cancer, patients with benign breast diseases and age-matched healthy controls showed that these proteins are highly specific and sensitive biomarkers for the early detection of human breast cancer in women of all ages. 

In addition, this method may be used for the determination of a patient`s prognosis and of therapy efficacy within the scope of personalized medicine.

Commercial Opportunities

Breast cancer is one of the most common types of cancer and a major cause of death in women. High rates of false negative and false positive results in young patients make the use of mammography in women younger than 50 years of age controversial.

Keywords: Brustkrebs, breast cancer, Diagnose, Prognose, diagnosis, prognosis, marker, women disease, cancer

Due to the limitations of mammography and clinical breast examination there is still an urgent need for a solid screening tool that enables an easy and trustworthy diagnosis during prophylactic medical examinations.

The present invention provides the two proteins CALML5 and CNN2 for the use as such markers.

Current Status

On behalf of the University of Bonn, PROvendis offers a patent license and/or research collaboration with licensing option. In case of interest we will be pleased to inform you about the current patent status.

bitte Kontaktieren Sie mich zu diesem angebot.

Dr. Silvia Schön-Feltes
+49.208 94105-46

Dr. Silvia Schön-Feltes

Dieses Angebot


PROvendis GmbH · Schloßstr. 11 – 15
D – 45468 Mülheim an der Ruhr
T +49 (0)208 94105-0 ·

Gefördert durch